211 related articles for article (PubMed ID: 31088302)
21. New paradigms in venous thromboprophylaxis of medically ill patients.
Spyropoulos AC; Raskob GE
Thromb Haemost; 2017 Aug; 117(9):1662-1670. PubMed ID: 28640324
[TBL] [Abstract][Full Text] [Related]
22. A clinical focus on the use of extended-duration thromboprophylaxis in medically ill patients.
Snoga JL; Benitez RM; Kim S; Creager O; Lusk KA
Am J Health Syst Pharm; 2021 Jun; 78(12):1057-1065. PubMed ID: 33580664
[TBL] [Abstract][Full Text] [Related]
23. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure.
Mebazaa A; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Merli G; Schellong SW; Spyropoulos AC; Tapson VF; De Sanctis Y; Cohen AT
Circulation; 2014 Jul; 130(5):410-8. PubMed ID: 24970782
[TBL] [Abstract][Full Text] [Related]
24. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.
Mahan CE; Fisher MD; Mills RM; Fields LE; Stephenson JJ; Fu AC; Spyropoulos AC
Thromb Res; 2013 Nov; 132(5):520-6. PubMed ID: 24080150
[TBL] [Abstract][Full Text] [Related]
25. Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.
Nafee T; Gibson CM; Yee MK; Alkhalfan F; Chi G; Travis R; Mir M; Kalayci A; Jafarizade M; Ganti A; Kazmi SH; Ghaffarpasand E; Pitliya A; Datta S; Sharfaei S; Alihashemi M; Elsaiey A; Qamar I; Jahansouz M; Talib U; Kahe F; Habibi S; Abdelwahed M; Tariq F; Kaur M; Younes A; Walia SS; Singh A; Dildar SM; Afzal MK; Kerneis M
Expert Rev Cardiovasc Ther; 2018 Nov; 16(11):845-855. PubMed ID: 30296387
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban for prevention and treatment of venous thromboembolism.
Chan NC; Weitz JI
Future Cardiol; 2019 Mar; 15(2):63-77. PubMed ID: 30779598
[TBL] [Abstract][Full Text] [Related]
27. Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients.
Cave B; Hough A; Dobesh PP
Pharmacotherapy; 2018 Jun; 38(6):597-609. PubMed ID: 29543384
[TBL] [Abstract][Full Text] [Related]
28. Betrixaban for prevention of venous thromboembolism in acute medically ill patients.
Beyer-Westendorf J; Verhamme P; Bauersachs R
Eur Heart J Suppl; 2018 May; 20(Suppl E):E16-E22. PubMed ID: 29977165
[TBL] [Abstract][Full Text] [Related]
29. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US.
Amin A; Deitelzweig S; Bucior I; Lin J; Lingohr-Smith M; Menges B; Neuman WR
J Med Econ; 2019 Nov; 22(11):1119-1125. PubMed ID: 31084383
[No Abstract] [Full Text] [Related]
30. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients.
Amin AN; Varker H; Princic N; Lin J; Thompson S; Johnston S
J Hosp Med; 2012 Mar; 7(3):231-8. PubMed ID: 22190427
[TBL] [Abstract][Full Text] [Related]
31. To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients.
Spyropoulos AC
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):506-514. PubMed ID: 36485109
[TBL] [Abstract][Full Text] [Related]
32. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
33. Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis.
Spyropoulos AC; Lipardi C; Xu J; Peluso C; Spiro TE; De Sanctis Y; Barnathan ES; Raskob GE
TH Open; 2020 Jan; 4(1):e59-e65. PubMed ID: 32190813
[TBL] [Abstract][Full Text] [Related]
34. Betrixaban: A Novel Factor Xa Inhibitor for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients.
Lee K; Cham S; Lam S
Cardiol Rev; 2018; 26(6):331-338. PubMed ID: 30067518
[TBL] [Abstract][Full Text] [Related]
35. Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment.
Al Yami MS; Kurdi S; Abraham I
J Blood Med; 2018; 9():25-34. PubMed ID: 29503590
[TBL] [Abstract][Full Text] [Related]
36. Venous Thromboembolism Prophylaxis and Risk in the Inpatient and Outpatient Continuum of Care Among Hospitalized Acutely Ill Patients in the US: A Retrospective Analysis.
Amin A; Neuman WR; Lingohr-Smith M; Menges B; Lin J
Adv Ther; 2019 Jan; 36(1):59-71. PubMed ID: 30543037
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary Venous Thromboembolism in an Acutely Ill Medical Patient Receiving Rivaroxaban.
Saleem A
J Coll Physicians Surg Pak; 2017 Sep; 27(9):S129-S130. PubMed ID: 28969751
[TBL] [Abstract][Full Text] [Related]
38. Reducing the burden of venous thromboembolism in the acute medically ill population with extended-duration thromboprophylaxis.
Ageno W; Hunt BJ
Eur Heart J Suppl; 2018 May; 20(Suppl E):E6-E11. PubMed ID: 29977163
[TBL] [Abstract][Full Text] [Related]
39. Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No.
Marongiu F; Barcellona D
Intern Emerg Med; 2018 Oct; 13(7):1015-1018. PubMed ID: 29594815
[TBL] [Abstract][Full Text] [Related]
40. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start).
Amin A; Spyropoulos AC; Dobesh P; Shorr A; Hussein M; Mozaffari E; Benner JS
J Thromb Thrombolysis; 2010 Apr; 29(3):326-39. PubMed ID: 19548071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
